Bliss GVS Pharma jumps 20% on Anupam stake deal 2026

What sparked the sudden move in Bliss GVS Pharma

Bliss GVS Pharma Ltd, a micro-cap name in the Pharmaceuticals & Biotechnology space, saw a sharp re-rating in late May after a change-of-control transaction was announced. Shares hit the 20% upper circuit on 26 May 2026 after specialty chemicals maker Anupam Rasayan India said it would acquire a large stake in the company. The announcement coincided with heavy volumes, new highs, and strong technical signals that sustained the move across multiple sessions.

The surge came amid mixed broader-market cues. In one session, the stock opened with a gap up of 9.66% and still finished 5.80% higher at ₹317.60, outperforming the Sensex rise of 1.23%. Over several updates captured in market data, the stock kept extending its winning streak, reflecting both event-driven interest and momentum-led participation.

Deal details: stake purchase and open offer

Anupam Rasayan said it has entered into a definitive agreement to acquire 43.3% to 48.2% equity stake in Bliss GVS Pharma and would make an open offer to public shareholders. The stated acquisition price in the filing was ₹299 per share for a 43.3% stake, with the overall transaction value cited at ₹1,369.51 crore. Under the takeover rules, the acquisition triggers a mandatory open offer for an additional 26% stake at ₹299 per share.

Anupam Rasayan India Managing Director Anand Desai said the transaction would strengthen the company’s presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations. The company also said the combination would create an integrated pharmaceutical manufacturing platform with deeper backward integration and a wider reach in regulated markets including Europe and the United States, aided by its earlier acquisition of Jayhawk.

How the stock traded: upper circuit, gaps, and streaks

On 26 May 2026, Bliss GVS Pharma closed at ₹381.10, up 20.0%, as it hit the upper circuit. The same update noted the move came against the previous close of ₹317.60 on the BSE. Across subsequent sessions referenced in the data, the rally extended into a multi-day streak.

The stock was also tracked at ₹427.65, up ₹31.30 (7.90%) in one market snapshot, while another update put the “current share price” at ₹425.3. These prints underscore that price discovery continued well beyond the upper circuit day, with heightened volatility.

Performance summaries in the provided data show the stock registering four, five, six, and seven consecutive days of gains at different points, with cumulative returns of 13.67%, 24.96%, 34.9%, and 45.18% over those periods. A separate performance note highlighted a 41.51% weekly gain, while another comparison showed a one-week gain of 29.91% versus the Sensex at 0.73%.

New highs and the scale of the one-year move

On 27 May 2026, Bliss GVS Pharma surged to an intraday peak of ₹392.40, setting a new 52-week and all-time high. The same note highlighted the magnitude of the longer-term move: from a 52-week low of ₹118.35, the stock was up 231.6% over the past year.

Even on a day when the stock dipped 0.97%, it remained aligned with the sector’s trend and stayed elevated on multi-session momentum. The data also flagged very high intraday volatility of 60.07%, signalling active trading and rapid intraday swings.

Technical picture: moving averages strong, RSI in overbought zone

Multiple technical indicators in the data pointed to bullish momentum. MACD, Bollinger Bands, KST, Dow Theory signals, and On-Balance Volume (OBV) were described as bullish on weekly and monthly charts. The stock was also stated to be trading above all key moving averages, including 5-day, 20-day, 50-day, 100-day, and 200-day averages.

At the same time, the Relative Strength Index (RSI) signalled caution in parts of the coverage. One update said the upper-circuit rally pushed the stock into the overbought zone with RSI at 74.4, where readings above 70 typically indicate an overbought condition.

Volumes and delivery: participation jumped sharply

Market activity spiked alongside the price move. On 26 May 2026, traded volume was reported at 53.93 lakh shares, with delivery volume accounting for 30.80% of total volume, well above the 5-day average volume of 14.76 lakh shares. Delivery trends were also described as rising sharply, including a 1-day delivery change of 265.27% versus the 5-day average and a 1-month delivery increase of 49.23%.

Earlier in the year, on 7 January 2026, the stock was highlighted as one of the most actively traded by volume, with total traded volume of 1.62 crore shares. On 6 January 2026, delivery volume was said to have surged to 65.04 lakh shares, up 1803.28% compared to the five-day average delivery volume.

Fundamentals: profit jump, valuation premium, and earnings drivers

The rally was also supported by improving profitability metrics cited in the data. Bliss GVS Pharma’s net profit jumped 128.96% year-on-year to ₹35.58 crore in Q4 2025-2026. On a sequential basis, net profit was up 52.9% versus the prior quarter.

Valuation multiples were described as premium as of 27 May 2026, with a trailing twelve months P/E of 31x and P/BV of 3.38x. Separate commentary noted that valuation multiples have expanded but were being supported by robust earnings growth and a solid financial position.

An earnings analysis note listed three growth catalysts: nine-month growth momentum continuing to FY26, interest cost reduction providing bottom-line relief, and tax rate normalization. It also cited “volatile other income” as a factor, with other income rising to ₹18.46 crore in Q3 FY26 from ₹8.46 crore in the previous quarter. Another expectation mentioned was “Q4 FY26” with “+₹10 crore revenue” as the potential impact, linked to 15.13% revenue growth and 32.78% PAT growth expected to drive full-year results.

Key data points at a glance

Market impact: what investors are reacting to

The immediate market impact was a rapid repricing in Bliss GVS Pharma, with the stock repeatedly outperforming both the Sensex and sector benchmarks in the cited sessions. One data point explicitly said the stock outperformed its sector by 11.5% even when the Sensex slipped 0.17%. Such divergence suggests that the move was driven by company-specific news rather than broad market beta.

The open offer price of ₹299 per share also became an anchor point for market participants when compared with the much higher trading prints reported after the announcement. At the same time, elevated RSI readings and high intraday volatility indicate that the stock’s run-up involved momentum-driven activity, which can lead to sharp swings.

Analysis: why the deal matters for the sector narrative

The proposed acquisition is notable because it links a specialty chemicals manufacturer with a formulations player, implying a push toward vertical integration. Anupam Rasayan’s stated rationale focused on strengthening its position across the pharmaceutical value chain and expanding reach in regulated markets such as Europe and the United States, with references to USFDA-approved facilities and global supply chains.

For Bliss GVS Pharma, the deal announcement arrived alongside reported strong profit growth and a bullish technical setup. But the data also flags risk markers that investors typically track in micro-cap rallies, including overbought RSI signals and unusually high volatility. Any sustainable re-rating would still depend on follow-through in earnings delivery and clarity on transaction timelines and approvals, as disclosed through filings.

Conclusion

Bliss GVS Pharma’s late-May rally was driven by Anupam Rasayan’s announcement to acquire a 43.3% to 48.2% stake and initiate a mandatory open offer, amplifying an already strong technical uptrend. The move also came with supportive fundamentals, including a 128.96% year-on-year jump in Q4 2025-2026 net profit to ₹35.58 crore and premium valuation multiples cited at 31x P/E and 3.38x P/BV.

Going forward, market attention is likely to stay on transaction execution steps, open offer details, and subsequent disclosures from both companies, alongside whether volatility cools as the stock consolidates near recent highs.